BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Knome Appoints Heidi L. Rehm, PhD, to Scientific Advisory Board


7/9/2012 10:19:00 AM

CAMBRIDGE, MA – July 9, 2012— Knome Inc., the human genome interpretation company, announced today that a leading clinical geneticist, Heidi Rehm, PhD, has joined the company’s scientific advisory board.

“Dr. Rehm is highly respected and influential figure in clinical genomics,” said Martin Tolar, MD, PhD, Chief Executive Officer of Knome. “We are very pleased to welcome Dr. Rehm to our scientific advisory board and look forward to her guidance as we deploy our informatics and interpretation technology into the clinic.”

Dr. Rehm is a board-certified clinical geneticist who is currently Chief Laboratory Director of the Laboratory for Molecular Medicine at Partners HealthCare Center for Personalized Genetic Medicine as well as Assistant Professor of Pathology and Director of the Clinical Molecular Genetics Training Program at Harvard Medical School. Her research focuses on the rapid translation of new genetic discoveries into clinical tests and on bringing novel technologies and software systems into molecular diagnostics to support the integration of genetics into clinical use. Dr. Rehm also conducts research on hearing loss, Usher syndrome, cardiomyopathy and the use of information technology in enabling personalized medicine. She received a PhD in Genetics from Harvard University and conducted postdoctoral work in Neurobiology, followed by a fellowship at Harvard Medical School in Clinical Molecular Genetics.

“Knome has assembled a first-class team of scientific, engineering, and business leaders—all focused on tackling a challenging but critically important mission—the interpretation of human genomes for medical and biological relevance,” said Dr. Rehm. “I am pleased to join Knome’s scientific advisory board and look forward to guiding the company as it pursues this mission.”

Heidi Rehm joins other members of Knome’s scientific advisory board:

• George Church, PhD, Knome Co-Founder and Chair of the Scientific Advisory Board, Professor of Genetics at Harvard Medical School and Director of the Center for Computational Genetics;

• Yaniv Erlich, PhD, Andria and Paul Heafy Family Fellow and Principal Investigator at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology;

• David Goldstein, PhD, Professor of Molecular Genetics and Microbiology, Professor of Biology and Director of the Center for Human Genome Variation at Duke University;

• Anthony Sinskey, ScD, Professor of Microbiology and Health Sciences and Technology at the Massachusetts Institute of Technology;

• Lincoln Stein, MD, PhD, Professor at Cold Spring Harbor Laboratory and Platform Leader of Informatics and Biocomputing at the Ontario Institute for Cancer Research; and

• Hugh Rienhoff, MD, Managing Director of Life Science Venture Partners.

About Knome

Knome Inc. (www.knome.com) is a leading provider of human genome interpretation software and services. Clients use our innovative solutions to identify the genetic basis of disease, tumor growth, and drug response. Designed to accelerate the process of interpreting whole genomes and enable the clinical application of genomic findings, Knome’s technologies are helping to pave the healthcare industry’s transition to molecular-based, personalized medicine.


Read at BioSpace.com


Knome
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->